Photo: William Stewart Halsted father of modern surgery.
Joined July 2011
- Tweets 3,918
- Following 100
- Followers 897
- Likes 28,240
966 Photos and videos
15m
$ALKS : Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies, Alkermes has initiated a global phase 3 program evaluating once-daily and split dose regimens of alixorexton in patients with NT1 and NT2.
share.google/DPCRq7NzxwuKEuA…
38
Jun 16
$FOCL : High Intensity Focused Ultrasound (HIFU) Gaining Traction In The Minimally invasive Treatment Of Prostate Cancer. share.google/FjxvLiwlKxLTpdk…
2
137
Jun 12
$INSM (BUY): Brinsupri Symphony Data Shows M/M Growth.
Bronchiectasis a very difficult pulmonary condition to treat.
2
366
Jun 12
$MBX BIOSCIENCES ANNOUNCES ONE-YEAR DATA DEMONSTRATING SUSTAINED BENEFIT OF ONCE-WEEKLY CANVUPARATIDE AS A POTENTIAL PTH REPLACEMENT THERAPY IN CHRONIC HYPOPARATHYROIDISM share.google/hiIktVBuT6Uwt5b…
1
331
Jun 10
“Published in Neurology, investigators reported that patients treated with the $NPCE RNS System experienced a median 82% reduction in seizure frequency at 3 years, with more than 40% achieving at least a 90% reduction in seizures”. share.google/FumlbrDjI3zbojs…
1
4
185
Will retweeted
Jun 10
SCOOP: Meet Susan Dinsmore, a licensed therapist at @SanfordHealth. She allegedly made this post online cheerfully asking if President Trump "is dead yet."
We reached out to Sanford Health multiple times for comment but they did not respond.
Would you trust this person with your mental health?
2,077
14,046
21,970
278,497
Jun 9
“By tracers, Dr. Zimberg's system exclusively uses Pylarify in the NY area and believes $LNTH will retain its dominant position, given its first-mover advantage”.
2
261
Jun 7
Amazing to see what has been created by one man: #SpaceX IPO. share.google/Qc97oBsHlyfFZnD…
2
154
Jun 5
$HUMA trial results due June 11. Are they preparing the market?
Women with AV Access face clear unmet needs.
• 50% fail AVF maturation (vs. 37% in men)1
• 30% use catheter for hemodialysis (vs. 24% in men)1
• 2× higher risk of catheter dysfunction2
• 1 in 2 use infection-prone access – catheters and synthetic grafts1
Be part of the conversation advancing care for women.
VISIT our MEDICAL INFROMATION TEAM at SVS - BOOTH #307
Learn more about Humacyte here: humacyte.com
For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
REFERENCES: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.
Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.
#Humacyte #Innovation #Biotech #VAM2026 #SVS $HUMA #HealthcareInnovation #WomenInMedicine #VascularCare
1
3
522
Jun 5
$LULU : A once loved clothing brand, now considered overly expensive. Quite a statement by Jefferies analyst.
1
1
439
Jun 4
$ALKS: Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research share.google/Me70rvAQNvL2IIw…
206
Jun 4
$NUVB : Company continues to make progress. Founder & CEO David Hung is a dynamic creator of value.
11
592
Will retweeted
Jun 4
We are excited to showcase @FocalOneHIFU at the 2026 British Association of Urological Surgeons (@BAUSurology) Annual Meeting, a flagship event in the field of urology, highlighting the latest developments in clinical practice, surgical innovation, and research in the UK.
Join us in London from June 15-17 to discover the latest generation Focal One® i system, explore its role in focal therapy, and connect with our team.
Schedule a Hands-On Simulation at our booth: events.focalone.com/baus2026.
#BAUS2026 | #RoboticSurgery | #MedTech | #HIFU | #Cancer | #ProstateCancer | #Urology
2
2
287
Will retweeted
Jun 3
Always a highlight connecting with the epilepsy community at #ASSFN2026.
Wonderful to see Dr. John Rolston and Dr. Mark Richardson with our own Dr. Martha Morrell. Our Breakfast Symposium on responsive thalamic neuromodulation for drug-resistant epilepsy drew a packed room of clinicians eager to discuss patient selection, emerging data and where the field is heading. The energy and depth of conversation was a testament to how much interest there is in this space. There is clear momentum building around this approach and we are grateful to be part of advancing it.
Thank you to everyone who joined us.
To learn more about the NeuroPace RNS® System, visit neuropace.com.
Safety info: neuropace.com/safety
#NeuroPace #ASSFN #RNSSystem #Epilepsy #NeurologyInnovation
1
1
4
252
Jun 2
SystImmune and $BMY potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types share.google/dCjeXJgKKkuM46A…
1
184
Jun 2
With regard to cancer signal attributed to $ABBX molecule; those old enough to remember secondary primary malignancy potential associated with Lenalidomide (Revlimid) use. The debate and overhang persisted for quite sometime. Difficult to dispel that association with investors.
185
Jun 2
We are very constructive on the setup for $LNTH in '26-27 and continue to see shares as undervalued; Buy. Management “not commenting on take-out headlines.”
2
322
Jun 2
1
1,326